GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » North China Pharmaceutical Co Ltd (SHSE:600812) » Definitions » Debt-to-EBITDA

North China Pharmaceutical Co (SHSE:600812) Debt-to-EBITDA : 16.01 (As of Sep. 2024)


View and export this data going back to 1994. Start your Free Trial

What is North China Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

North China Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥7,548 Mil. North China Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥3,988 Mil. North China Pharmaceutical Co's annualized EBITDA for the quarter that ended in Sep. 2024 was ¥721 Mil. North China Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 16.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for North China Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:600812' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 6.42   Med: 7.53   Max: 15.97
Current: 15.97

During the past 13 years, the highest Debt-to-EBITDA Ratio of North China Pharmaceutical Co was 15.97. The lowest was 6.42. And the median was 7.53.

SHSE:600812's Debt-to-EBITDA is ranked worse than
95.73% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs SHSE:600812: 15.97

North China Pharmaceutical Co Debt-to-EBITDA Historical Data

The historical data trend for North China Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

North China Pharmaceutical Co Debt-to-EBITDA Chart

North China Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.42 9.62 9.30 13.58 7.25

North China Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.93 18.14 15.38 13.65 16.01

Competitive Comparison of North China Pharmaceutical Co's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, North China Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


North China Pharmaceutical Co's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, North China Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where North China Pharmaceutical Co's Debt-to-EBITDA falls into.



North China Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

North China Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6767.572 + 4380.019) / 1538.477
=7.25

North China Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7548.367 + 3988.071) / 720.732
=16.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


North China Pharmaceutical Co  (SHSE:600812) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


North China Pharmaceutical Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of North China Pharmaceutical Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


North China Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 388 Heping East Road, Shijiazhuang, Hebei, CHN, 050015
North China Pharmaceutical Co Ltd is engaged in the manufacture and sale of antibiotics, vitamins, and pharmaceutical products in China. The main products include antibiotics such as penicillin, vitamins, cephalosporins, streptomycin, biotechnological drugs, new preparations, and biological products.
Executives
Gao Ren Long senior management
Lian Fa Zhe Director

North China Pharmaceutical Co Headlines

No Headlines